Home LiteratureArticle Details
PMID: 10691920 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection.

Clinical and experimental immunology ·Vol. 119 ·No. 3 ·2000-03-00 ·Pages 479-85

Stylianou E, Aukrust P, Bendtzen K, Müller F, Frøland SS

Abstract

Interferons play an important, but incompletely understood role in HIV-related disease. We investigated the effect of HAART on plasma levels of IFN-alpha, IFN-gamma, neopterin and interferon-inducible protein 10 (IP-10) in 41 HIV-infected patients during 78 weeks of therapy. At baseline HIV-infected patients had raised levels of both IP-10 and IFN-alpha compared with healthy controls (n = 19), with particularly high levels in advanced disease. HAART induced a marked decrease in levels of both IFN-alpha, neopterin and IP-10, though not to normal concentrations. In contrast, IFN-gamma levels were low throughout the study, and not different from controls. While neopterin and IP-10 remained significantly decreased compared with baseline levels throughout the study, IFN-alpha levels returned to baseline at the end of the study. Persistently high IP-10 and IFN-alpha levels were associated with immunological treatment failure and even high baseline levels of IFN-alpha appeared to predict immunological relapse. Furthermore, we found a markedly suppressive effect of exogenously added IFN-alpha on phytohaemagglutinin-stimulated lymphocyte proliferation in both patients and controls, and this suppressive effect seemed not to involve enhanced lymphocyte apoptosis. Our findings suggest a pathogenic role of IFN-alpha in HIV infection, which may be a potential target for immunomodulating therapy in combination with HAART.

MeSH Terms
Anti-HIV Agents/therapeutic use Chemokine CXCL10 Chemokines, CXC/immunology HIV Infections/drug therapy,immunology Humans Immunosuppression Therapy Interferon-alpha/immunology Neopterin/immunology
Chemicals
Anti-HIV Agents Chemokine CXCL10 Chemokines, CXC Interferon-alpha Neopterin
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Stylianou E
Section of Clinical Immunology and Infectious Diseases and Research Institute for Internal Medicine, Medical Department, Rikshospitalet, Oslo, Norway. [email protected]
Aukrust P
Bendtzen K
Müller F
Frøland S S
References (43)
43 references, click to expand
  1. Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection.
    Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):634-9 PMID: 9012836
  2. Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes.
    Blood. 1996 Jun 1;87(11):4731-6 PMID: 8639843
  3. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily.
    Cytokine Growth Factor Rev. 1997 Sep;8(3):207-19 PMID: 9462486
  4. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections.
    Semin Immunol. 1998 Oct;10(5):383-90 PMID: 9799713
  5. Cytokines and cytokine therapies in HIV infection.
    AIDS Clin Rev. 1997-1998;:187-228 PMID: 9305449
  6. Interferons in the persistence, pathogenesis, and treatment of HIV infection.
    AIDS Res Hum Retroviruses. 1992 Feb;8(2):199-207 PMID: 1371692
  7. Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Sep;13(1):55-67 PMID: 8797687
  8. Human interferon-gamma-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.
    J Exp Med. 1998 Jul 20;188(2):405-8 PMID: 9670053
  9. Impaired in vitro survival of monocytes from patients with HIV infection.
    Clin Exp Immunol. 1990 Jul;81(1):25-30 PMID: 1974179
  10. Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals.
    AIDS Res Hum Retroviruses. 1997 Aug 10;13(12):1039-46 PMID: 9264291
  11. A TH1-->TH2 switch is a critical step in the etiology of HIV infection.
    Immunol Today. 1993 Mar;14(3):107-11 PMID: 8096699
  12. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.
    J Infect Dis. 1996 Feb;173(2):321-9 PMID: 8568292
  13. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters.
    J Infect Dis. 1994 Feb;169(2):420-4 PMID: 7906293
  14. Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual.
    Clin Infect Dis. 1993 Oct;17(4):749-71 PMID: 8268360
  15. Simultaneous determination of cell surface antigens and apoptosis.
    Trends Genet. 1994 Feb;10(2):41-2 PMID: 8191583
  16. Identification of CRG-2. An interferon-inducible mRNA predicted to encode a murine monokine.
    J Biol Chem. 1990 Sep 5;265(25):15049-57 PMID: 2118520
  17. Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21.
    Eur Cytokine Netw. 1998 Dec;9(4):619-31 PMID: 9889406
  18. Flow cytometric determination of apoptosis in heterogeneous cell populations.
    J Immunol Methods. 1995 Mar 13;180(1):131-40 PMID: 7897243
  19. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines.
    Blood. 1998 Oct 15;92(8):2914-23 PMID: 9763578
  20. How immune-based interventions can change HIV therapy.
    Nat Med. 1997 May;3(5):483-6 PMID: 9142107
  21. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses.
    FASEB J. 1998 Jun;12(9):705-13 PMID: 9619449
  22. Interferons in the pathogenesis and treatment of human immunodeficiency virus infection.
    Antiviral Res. 1994 Jul;24(2-3):221-33 PMID: 7526793
  23. A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection.
    J Infect Dis. 1994 May;169(5):981-9 PMID: 7909550
  24. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection.
    AIDS Res Hum Retroviruses. 1991 Apr;7(4):375-80 PMID: 1906289
  25. Direct immunomagnetic quantification of lymphocyte subsets in blood.
    Clin Exp Immunol. 1988 Jan;71(1):182-6 PMID: 3349645
  26. Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection.
    J Infect Dis. 1994 Jun;169(6):1351-5 PMID: 7910838
  27. Differential gene expression of IFN-alpha and tumor necrosis factor-alpha in peripheral blood mononuclear cells from patients with AIDS related complex and AIDS.
    J Immunol. 1990 Feb 1;144(3):970-5 PMID: 2295823
  28. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.
    MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 PMID: 1361652
  29. Host factors and the pathogenesis of HIV-induced disease.
    Nature. 1996 Dec 12;384(6609):529-34 PMID: 8955267
  30. Cytokine therapeutics: lessons from interferon alpha.
    Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205 PMID: 8108387
  31. Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome.
    N Engl J Med. 1984 Apr 5;310(14):883-9 PMID: 6422299
  32. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes.
    J Exp Med. 1996 Sep 1;184(3):963-9 PMID: 9064356
  33. The interferons. Mechanisms of action and clinical applications.
    JAMA. 1991 Sep 11;266(10):1375-83 PMID: 1715409
  34. Cellular responses to interferon-gamma.
    Annu Rev Immunol. 1997;15:749-95 PMID: 9143706
  35. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity.
    J Infect Dis. 1996 May;173(5):1107-14 PMID: 8627061
  36. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
    J Clin Invest. 1995 May;95(5):1974-8 PMID: 7738163
  37. Immunology of HIV infection, I: Biology of the interferons.
    AIDS Res Hum Retroviruses. 1990 Oct;6(10):1149-56 PMID: 1701313
  38. Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions.
    J Immunol Methods. 1992 Aug 30;153(1-2):115-24 PMID: 1381403
  39. How cells respond to interferons.
    Annu Rev Biochem. 1998;67:227-64 PMID: 9759489
  40. Constitutive expression of interferon gamma-inducible protein 10 in lymphoid organs and inducible expression in T cells and thymocytes.
    J Exp Med. 1994 Apr 1;179(4):1373-8 PMID: 8145049
  41. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells.
    Science. 1994 Jul 8;265(5169):244-8 PMID: 8023142
  42. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.
    Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6 PMID: 9520456
  43. Relationship and prognostic value of endogenous interferon-alpha, beta 2-microglobulin, and neopterin serum levels in patients with Kaposi sarcoma and AIDS.
    J Acquir Immune Defic Syndr. 1991;4(9):871-80 PMID: 1895208
Article Info
Journal
Clinical and experimental immunology
Abbr.
Clin Exp Immunol
ISSN
0009-9104
Published
2000-03-00
Pages
479-85
Language
English
Region
England
NLM ID
0057202
PMCID
PMC1905596
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]